Functional loss of ARID1a, a frequently mutated tumor suppressor gene, causes deficiencies in normal DNA repair and may sensitize tumors to immune checkpoint blockade therapies, according to researchers from The University ...
May 7, 2018
0
26
Published in Nature Aging, University of Minnesota Medical School researchers have provided new insight into enhancing immune responses in older individuals and the potential for using immunotherapy to make older adults less ...
May 15, 2024
0
56
The oncogenic activation of MYC, a critical gene in cancer progression, has the potential to identify lung cancer patients who may respond poorly to immunotherapy (ICB). This is the main conclusion of a study recently published ...
Apr 14, 2023
0
54
Researchers from The University of Texas MD Anderson Cancer Center found specific intestinal microbiota signatures correlate with high-grade adverse events and response to combined CTLA-4 and PD-1 blockade treatment. The ...
Jul 8, 2021
0
8
One of the trickiest parts of treating brain conditions is the blood brain barrier, a blockade of cells that prevent both harmful toxins and helpful pharmaceuticals from getting to the body's control center. But, a technique ...
Mar 13, 2012
0
1
Scientists at the MedUni Vienna, in collaboration with a working group led by Nancy Hynes at the University of Basel, have discovered a new approach in the treatment of breast cancer: an international team involving the Clinical ...
Aug 8, 2013
0
0
In a Phase II clinical trial, immune checkpoint blockade before surgery was associated with favorable responses and outcomes in undifferentiated pleomorphic sarcoma (UPS) and recurrent dedifferentiated liposarcoma (DDLPS), ...
Jun 6, 2022
0
11
Two new studies indicate that immunotherapy may benefit people with leptomeningeal carcinomatosis (LMD), a rare but serious complication of cancer that has spread to the brain and/or spinal cord. The research, which was led ...
Oct 21, 2021
0
65
A Ludwig Cancer Research study has uncovered a cellular mechanism by which melanomas that fail to respond to checkpoint blockade may be made susceptible to immunotherapies. Led by Ping-Chih Ho of the Lausanne Branch of the ...
Jan 23, 2019
0
2
Scientists have made an unusual discovery that could help to identify patients who are up to two-and-a-half times more likely to respond to currently available cancer drugs.
Jan 29, 2024
0
91
